双成药业(002693) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥36,675,823.05, a decrease of 14.23% compared to ¥42,761,740.63 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥10,040,496.02, representing a decline of 14.84% from a loss of ¥8,742,676.77 in the previous year[4] - The company's basic and diluted earnings per share were both -¥0.0242, a decrease of 14.69% from -¥0.0211 in the same period last year[4] - Net loss attributable to the parent company was CNY -10,040,496.02, compared to CNY -8,742,676.77 in the previous period, indicating a worsening of approximately 14.8%[20] Cash Flow - The net cash flow from operating activities improved significantly, with a net outflow of ¥4,836,758.99, a 79.54% increase compared to a net outflow of ¥23,640,127.59 last year[4] - The net cash flow from operating activities was -$4,836,758.99, an improvement from -$23,640,127.59 in the previous period[22] - Cash inflow from operating activities was CNY 41,202,488.27, down from CNY 46,288,023.21, a decrease of about 10.4% year-over-year[21] - Total cash outflow from operating activities decreased to $46,039,247.26 from $69,928,150.80[22] - Cash inflow from investment activities increased significantly to $86,578,478.38 compared to $46,581,555.73 in the prior period[22] - The net cash flow from investment activities was -$36,775,305.73, a decline from $13,456,988.93 previously[22] - Cash inflow from financing activities totaled $3,709,560.00, down from $25,931,612.24 in the last period[22] - The net cash flow from financing activities was -$147,635.85, a significant drop from $24,469,778.91[22] - The net increase in cash and cash equivalents decreased by 391.43% compared to the previous year, influenced by operating, investing, and financing activities[10] - The ending balance of cash and cash equivalents decreased to $3,439,716.44 from $17,684,279.51[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥762,219,967.93, down 2.76% from ¥783,866,026.52 at the end of the previous year[4] - Total current assets decreased from 155,969,514.43 RMB to 136,752,293.30 RMB, a reduction of approximately 12.3%[16] - Total liabilities decreased to CNY 364,114,607.47 from CNY 372,260,377.26, a decline of approximately 2.9%[17] - Current liabilities totaled CNY 170,971,610.83, down from CNY 176,987,637.83, reflecting a decrease of about 3.4%[17] - Non-current liabilities decreased to CNY 193,142,996.64 from CNY 195,272,739.43, a reduction of approximately 1.1%[17] - Total equity decreased to CNY 398,105,360.46 from CNY 411,605,649.26, indicating a decline of about 3.3%[17] Expenses - Sales expenses decreased by 47.94% year-on-year, primarily due to reduced product sales and lower market development investments[9] - R&D expenses fell by 50.95% compared to the previous year, reflecting a decrease in research investments[9] - Total operating costs decreased to CNY 51,367,471.72 from CNY 57,356,433.81, a reduction of about 10.4% year-over-year[19] Other Income and Transactions - Other income increased by 197.15% year-on-year, mainly due to higher government subsidy income[9] - The total amount of related party transactions with Ningbo Shuangcheng Pharmaceutical Co., Ltd. is 3,748,680.00 RMB, covering a three-year contract[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 79,029[12] - The largest shareholder, Hainan Shuangcheng Investment Co., Ltd., holds 32.92% of shares, totaling 136,516,546 shares[12] Strategic Decisions - The company plans to terminate the acquisition of 100% equity in Ningbo Aola Semiconductor Co., Ltd. due to disagreements on transaction terms[13] - The company is actively pursuing strategic transactions and partnerships to enhance its market position[13] Accounting and Audit - The company did not undergo an audit for the first quarter report[23] - The new accounting standards will be first implemented starting in 2025[24]